Clinical Trial Detail

NCT ID NCT02861573
Title Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

prostate adenocarcinoma

Therapies

Dexamethasone + Docetaxel + Pembrolizumab + Prednisone

Olaparib + Pembrolizumab

Enzalutamide + Pembrolizumab

Age Groups: adult child

No variant requirements are available.